Browse the evidence

GIP antagonism has been shown to reduce the development of obesity in preclinical models.

GIP antagonism could be a potential strategy for obesity treatment.

There is a need to end disparities in cardiovascular morbidity and mortality related to race, sex, and income inequality.

Healthcare systems should implement strategies to reduce these disparities.

Fatty acids increase GDF15 levels dose dependently, with the greatest response observed with linolenic acid.

Incorporating fatty acids like linolenic acid may enhance GDF15 levels, potentially influencing dietary responses.

The effect of linolenic acid on food intake and body mass disappears in mice lacking the GDF15 receptor GFRAL.

The presence of the GFRAL receptor is essential for the appetite-suppressing effects of linolenic acid.

Semaglutide did not increase or reduce the risk of eye disorders (OR, 1.01; 95% CI, 0.91-1.12) or diabetic retinopathy (OR, 1.04; 95% CI, 0.92-1.17).

Semaglutide can be considered safe regarding eye disorders and diabetic retinopathy.

Manufacturer discounts for GLP1s approved for obesity were estimated at 41%, resulting in net prices of $717 to $761 per month of supply.

Practitioners should consider the significant discounts when discussing GLP1s with patients.

Manufacturer discounts for GLP1s approved for type 2 diabetes ranged from 54% to 59%, leading to net prices of $312 to $469 per month of supply.

Practitioners should be aware of the cost implications of GLP1s for type 2 diabetes when advising patients.

The magnitude of manufacturer discounts highlights the importance of considering net price information in coverage decision-making for GLP1s.

Healthcare decision-makers should factor in net prices when evaluating GLP1 coverage options.

Patients who had bariatric surgery for morbid obesity after liver transplantation had a 16% post-bariatric surgery major complication rate.

Caution is advised for patients undergoing bariatric surgery after liver transplantation due to a higher complication rate.

Gastrointestinal adverse events occur commonly with semaglutide, and other serious adverse events have been reported.

Healthcare providers should monitor patients for gastrointestinal and other serious adverse events while on semaglutide.

Dietary intake and biomarkers of total fat and saturated, monounsaturated, and polyunsaturated fatty acids were not associated with the risk of coronary events.

Practitioners should note that total fat and specific fatty acids do not appear to influence coronary event risk.

Challenges to scaling FIM programs include incorporating them into health care business models and educating the health care workforce.

Stakeholders should focus on developing business models and training programs to effectively scale FIM interventions.

The development of new uses and long-lasting preparations of GLP-1 drugs is crucial for future market potential.

Practitioners should stay informed about new formulations and uses of GLP-1 drugs to leverage their market potential.

Existing pharmacologic formulations for obesity have not provided optimal clinical efficacy and have had many concerning adverse effects.

Practitioners should be aware of the limitations and adverse effects of current obesity pharmacotherapies.

There are existing knowledge gaps in the molecular and cellular processes underlying exercise-induced benefits and adaptations.

Researchers should focus on addressing these gaps to advance the understanding of exercise physiology.

Fructose resets ATP levels to a lower level in the cell, suppressing mitochondrial function.

Understanding fructose's impact on ATP may inform dietary recommendations.

Statistical guidance and study designs are necessary to measure treatment response heterogeneity in nutrition and obesity research.

Researchers should adopt appropriate statistical methods and study designs to accurately assess treatment responses.

Understanding the pathophysiological traits of OSA in each patient is crucial for effective treatment.

Practitioners should assess individual pathophysiological traits to tailor OSA treatments.

The development of new drug combinations may provide alternative treatment options for OSA.

Practitioners should explore new drug combinations as potential treatments for OSA.

Tirzepatide treatment significantly decreased Alt-Ext-induced IL-5 and IL-13 levels in lung homogenates compared with vehicle treatment.

Tirzepatide may help reduce allergic inflammation in obese asthma patients.

Semaglutide treatment is not associated with higher rates of short-term adverse events after cervical spine decompression and fusion in patients with Type 2 Diabetes Mellitus.

Practitioners can consider that semaglutide treatment does not increase short-term surgical risks in this patient population.

There are no statistically significant differences in the composite measure of postoperative surgical complications between semaglutide-treated patients and controls.

The findings suggest that semaglutide does not negatively impact surgical outcomes in this context.

The 30-day and 90-day readmission rates were similar between semaglutide-treated patients and controls.

This indicates that semaglutide does not increase the likelihood of readmission after surgery.

There is a significant difference in the profile of reporting risk and time-to-onset of GADRs between semaglutide and liraglutide.

Understanding these differences can help tailor obesity treatment to individual patient needs.